Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Application of decoy oligonucleotides as novel therapeutic strategy: a contemporary overview.

Ahmad MZ, Akhter S, Mallik N, Anwar M, Tabassum W, Ahmad FJ.

Curr Drug Discov Technol. 2013 Mar;10(1):71-84. Review.

PMID:
22780867
2.

Gene therapy with transcription factor decoy oligonucleotides as a potential treatment for cardiovascular diseases.

Tomita N, Azuma H, Kaneda Y, Ogihara T, Morishita R.

Curr Drug Targets. 2003 May;4(4):339-46. Review.

PMID:
12699354
3.
4.

Development of novel decoy oligonucleotides: advantages of circular dumb-bell decoy.

Tomita N, Tomita T, Yuyama K, Tougan T, Tajima T, Ogihara T, Morishita R.

Curr Opin Mol Ther. 2003 Apr;5(2):107-12. Review.

PMID:
12772498
5.

Therapeutic potential of decoy oligonucleotides strategy in cardiovascular diseases.

Tomita N, Ogihara T, Morishita R.

Expert Rev Cardiovasc Ther. 2003 Sep;1(3):463-70. Review.

PMID:
15030273
6.

Therapeutic potential of oligonucleotide-based therapy in cardiovascular disease.

Morishita R, Kaneda Y, Ogihara T.

BioDrugs. 2003;17(6):383-9. Review.

PMID:
14614761
7.

Transcription factors as molecular targets: molecular mechanisms of decoy ODN and their design.

Tomita N, Ogihara T, Morishita R.

Curr Drug Targets. 2003 Nov;4(8):603-8. Review.

PMID:
14577649
8.

Potential therapeutic applications of decoy oligonucleotides.

Tomita N, Morishita R, Tomita T, Ogihara T.

Curr Opin Mol Ther. 2002 Apr;4(2):166-70. Review.

PMID:
12044038
9.

NFkappaB decoy oligonucleotides.

De Stefano D, De Rosa G, Carnuccio R.

Curr Opin Mol Ther. 2010 Apr;12(2):203-13. Review.

PMID:
20373264
10.

Noncoding oligonucleotides: the belle of the ball in gene therapy.

Shum KT, Rossi JJ.

Adv Genet. 2015;89:153-77. doi: 10.1016/bs.adgen.2014.10.004. Epub 2014 Dec 4.

PMID:
25620011
11.

Oligonucleotide-based gene therapy for cardiovascular disease: are oligonucleotide therapeutics novel cardiovascular drugs?

Morishita R, Aoki M, Kaneda Y.

Curr Drug Targets. 2000 Jul;1(1):15-23. Review.

PMID:
11475534
12.

[Application of decoy strategy].

Morishita R, Ogihara T.

Nihon Rinsho. 1996 Sep;54(9):2583-90. Review. Japanese.

PMID:
8890596
13.

Oligonucleotides decoy to NF-kappaB: becoming a reality?

De Stefano D.

Discov Med. 2011 Aug;12(63):97-105. Review.

14.

The potential of oligonucleotides for therapeutic applications.

Fichou Y, Férec C.

Trends Biotechnol. 2006 Dec;24(12):563-70. Epub 2006 Oct 12. Review.

PMID:
17045686
15.

Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model.

Kawamura I, Morishita R, Tomita N, Lacey E, Aketa M, Tsujimoto S, Manda T, Tomoi M, Kida I, Higaki J, Kaneda Y, Shimomura K, Ogihara T.

Gene Ther. 1999 Jan;6(1):91-7.

16.

Decoy oligodeoxynucleotides as novel cardiovascular drugs for cardiovascular disease.

Morishita R, Aoki M, Kaneda Y.

Ann N Y Acad Sci. 2001 Dec;947:294-301; discussion 301-2.

PMID:
11795277
17.

Transcription factor decoy oligonucleotide-based therapeutic strategy for renal disease.

Tomita N, Kashihara N, Morishita R.

Clin Exp Nephrol. 2007 Mar;11(1):7-17. Epub 2007 Mar 28. Review.

PMID:
17384993
18.

Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease.

Séguin RM, Ferrari N.

Expert Opin Investig Drugs. 2009 Oct;18(10):1505-17. doi: 10.1517/13543780903179294. Review.

PMID:
19715448
19.

Synthetic oligonucleotides as therapeutics: the coming of age.

Ma DD, Rede T, Naqvi NA, Cook PD.

Biotechnol Annu Rev. 2000;5:155-96. Review.

PMID:
10875000
20.

Application of decoy oligodeoxynucleotides-based approach to renal diseases.

Tomita N, Azuma H, Kaneda Y, Ogihara T, Morishita R.

Curr Drug Targets. 2004 Nov;5(8):717-33. Review.

PMID:
15578952
Items per page

Supplemental Content

Write to the Help Desk